Yüklüyor......

Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions

Ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 antibody, was the first therapy demonstrated to improve overall survival in melanoma. Since ipilimumab’s approval by the FDA in 2011, a wealth of data have amassed, helping clinicians to optimize its use. We have learned how to mitigate the advers...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Page, David B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3799873/
https://ncbi.nlm.nih.gov/pubmed/23933888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11912-013-0337-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!